What Is Melanotan 2?
Melanotan 2 (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed at the University of Arizona in the 1980s as part of a research program investigating melanocortin receptor pharmacology and photoprotective strategies for skin cancer prevention. The cyclic structure of MT-II, created by an internal lactam bridge, dramatically increases its potency and stability compared to native α-MSH, while broadening receptor affinity across the melanocortin family.
MT-II acts as a non-selective agonist at the melanocortin receptors MC1R (skin, hair), MC3R and MC4R (central nervous system, appetite, sexual function), and MC5R (exocrine function). This broad receptor activity is the basis for MT-II's combined research profile: melanogenesis via MC1R, appetite suppression via MC4R, and sexual-function effects via MC3R/MC4R. MT-II was the pharmacological parent compound from which PT-141 (Bremelanotide) was later developed as a more MC4R-focused analog.
Peptide Profile
Full Name: Melanotan 2 (MT-II) Acetate
Sequence: Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-NH₂
Molecular Weight: ~1,024 Da
Amino Acid Residues: 7 (cyclic heptapeptide)
Classification: Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R)
Original Developer: University of Arizona
Mechanism of Action
Melanotan 2 functions as a potent, non-selective agonist across the melanocortin receptor family. Unlike Melanotan 1, which is a linear peptide with selectivity for MC1R, MT-II's cyclic structure produces broad activity at multiple receptors, which explains its combined research footprint across pigmentation, appetite, and sexual function.
MC1R Activation & Melanogenesis
MT-II binds and activates MC1R on melanocytes, triggering a cAMP / PKA signaling cascade that increases tyrosinase expression and stimulates the production of eumelanin. In preclinical and applied research, this has been studied in the context of skin pigmentation darkening, UV-induced tanning responses, and photoprotective endpoints.
MC4R Activation & Appetite / Sexual Function
Activation of central MC4R by MT-II has been associated with two distinct research endpoints: reduced food intake and modulation of sexual function. MC4R is a key regulator of energy homeostasis and satiety signaling in the hypothalamus, and it also plays a central role in central sexual arousal pathways. These mechanisms underlie MT-II's research interest in obesity models and in sexual function research, the latter of which was further refined in the development of PT-141.
MC3R & MC5R Activity
MT-II also shows affinity for MC3R (involved in energy balance and inflammation) and MC5R (involved in exocrine function, sebum production, and thermoregulation). While these receptors are less prominent in MT-II's primary research applications, their activation contributes to its broad pharmacological signature and is part of what differentiates MT-II from the more receptor-selective PT-141.
Cyclic Structure & Stability
The internal lactam bridge of MT-II locks the peptide into a conformation that is both more receptor-potent and more resistant to enzymatic degradation than native α-MSH. This structural stability allows for subcutaneous dosing in research protocols and supports the extended duration of observed pharmacological effects relative to the linear parent hormone.
Research Overview
Melanotan 2 has been investigated across dermatological, metabolic, and neuropharmacological research. The following table summarizes key areas of investigation.
| Research Area | Key Findings | Study Type |
|---|---|---|
| Melanogenesis & Pigmentation | Studies demonstrate potent MC1R activation leading to increased eumelanin synthesis and measurable skin pigmentation changes | In vitro & in vivo (human) |
| Appetite Suppression (MC4R) | Preclinical research shows reduced food intake and body-weight gain in rodent models via central MC4R activation | In vivo (rodent) |
| Sexual Function | Clinical and preclinical research documents pro-erectile and arousal effects in male and female models, forming the mechanistic basis for PT-141's later development | In vivo (human/rodent) |
| Melanocortin Receptor Pharmacology | MT-II is widely used as a reference agonist in receptor binding and functional research across MC1R, MC3R, MC4R, and MC5R | In vitro |
| Photoprotection | Research has examined MC1R-driven eumelanin induction as a potential photoprotective mechanism against UV-induced skin damage | In vivo (preclinical) |
| Cardiovascular & Inflammatory Effects | Studies have explored melanocortin-receptor-mediated effects on blood pressure, inflammatory cytokine release, and autonomic signaling | In vivo (rodent) |
MT-II has one of the broadest research footprints of any synthetic melanocortin agonist. Its combined activity across MC1R, MC3R, MC4R, and MC5R makes it valuable as a pharmacological tool in receptor research, while the same broad profile underlies its applied research interest in pigmentation, appetite, and sexual function. PT-141 (Bremelanotide), which later received FDA approval for hypoactive sexual desire disorder, was derived from MT-II. A recurring safety theme in the MT-II literature is dermatologic: research and case reports have noted darkening and enlargement of melanocytic nevi (moles), and concern about melanoma has been raised, so dermatologic monitoring is emphasized in that work.
Common Areas of Research Interest
Scientific interest in MT-II spans dermatological, metabolic, and neurosexual research, all tied to its broad melanocortin receptor activity.
- Melanogenesis & pigmentation, MC1R-driven eumelanin synthesis and skin darkening is the most extensively studied research endpoint for MT-II
- Photoprotection research, Studies examine whether melanocortin-driven tanning responses can reduce UV-related skin damage
- Appetite & energy balance, MC4R-mediated reductions in food intake and body weight are documented in rodent research
- Sexual function, Pro-erectile and central arousal effects in preclinical and human research form the precursor literature for PT-141
- Melanocortin pharmacology, MT-II serves as a reference agonist for studying MC-receptor signaling, binding, and selectivity
- Inflammation & cardiovascular signaling, Research continues to explore melanocortin-receptor effects on inflammatory pathways and vascular tone
Pharmacokinetics
The pharmacokinetic profile of MT-II reflects its cyclic, stabilized structure. The following parameters summarize key pharmacokinetic characteristics reported in the literature.
The cyclic lactam bridge in MT-II markedly increases metabolic stability relative to native α-MSH, extending functional duration and receptor potency. MT-II is most commonly studied in research via subcutaneous injection after reconstitution with bacteriostatic water. Research protocols typically employ cycle-based dosing rather than continuous daily administration, to manage receptor desensitization and extend the observed pharmacological response.
MT-1 vs MT-2 vs PT-141, Side-by-Side
All three compounds are synthetic melanocortin receptor agonists derived from or inspired by the native α-MSH sequence, but they differ sharply in receptor selectivity, stability, and primary research focus. The following side-by-side comparison highlights those distinctions.
| Feature | Melanotan 1 (Afamelanotide) | Melanotan 2 (MT-II) | PT-141 (Bremelanotide) |
|---|---|---|---|
| Structure | Linear 13-residue α-MSH analog | Cyclic 7-residue α-MSH analog (lactam bridge) | Cyclic 7-residue analog (metabolite of MT-II) |
| Molecular Weight | ~1,647 Da | ~1,024 Da | ~1,025 Da |
| Receptor Selectivity | MC1R selective (with some MC3R/MC4R/MC5R activity) | Non-selective: MC1R, MC3R, MC4R, MC5R | Primarily MC3R & MC4R |
| Primary Research Focus | Melanogenesis & photoprotection | Melanogenesis + appetite + sexual function | Sexual function (HSDD research) |
| Secondary Effects | Minimal off-target activity | Appetite reduction, pigmentation, arousal | Minimal pigmentation or appetite effect |
| Regulatory Status | FDA & EMA approved as Scenesse (EPP) | Research compound only | FDA approved as Vyleesi (HSDD) |
| Typical Research Route | Subcutaneous implant (clinical); SC injection (research) | Subcutaneous injection | Subcutaneous injection |
| Side-Effect Profile (Research) | Narrow: facial flushing, mild nausea | Broad: nausea, appetite loss, arousal, pigmentation; darkening/enlargement of moles | Moderate: nausea, transient BP changes, facial flushing |
| Developed From | Modified α-MSH (13-residue) | Truncated / cyclized α-MSH (Arizona) | Metabolite of MT-II (Palatin) |
When researchers choose MT-1: when the study endpoint is pigmentation or photoprotection and minimal off-target melanocortin activity is desired.
When researchers choose MT-2: when the study requires broad melanocortin activity, particularly combined pigmentation + appetite + sexual function endpoints, or when MT-II is used as a reference agonist in receptor pharmacology research.
When researchers choose PT-141: when the focus is specifically on MC3R/MC4R-mediated sexual function pathways without meaningful pigmentation or appetite effects. PT-141 is the most receptor-selective and regulatory-mature of the three.
Frequently Asked Questions
Sources & References
- Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides. 2006;27(4):921-930. PubMed
- Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. "Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin." Journal of Medicinal Chemistry. 1989;32(12):2555-2561. PubMed
- Dorr RT, et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sciences. 1996;58(20):1777-1784. PubMed
- Levine N, et al. "Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin." JAMA. 1991;266(19):2730-2736. PubMed
- Wessells H, Gralnek D, Dorr R, et al. "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction." Urology. 2000;56(4):641-6. PubMed
- Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. "Role of melanocortinergic neurons in feeding and the agouti obesity syndrome." Nature. 1997;385(6612):165-168. PubMed
- Hruby VJ, Lu D, Sharma SD, et al. "Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors." J Med Chem. 1995;38(18):3454-61. PubMed
Explore Melanotan 2 10mg
Available for research purposes. Third-party tested for purity and identity.
View Melanotan 2 — $50This product is intended for research and laboratory use only. It is not intended for human consumption.